Alta Wealth Advisors’s 10x Genomics TXG Stock Holding History

Alta Wealth Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,523	Closed	-$222K	–	156
2021 Q3	$222K	Buy	+1,523	New	+$261K	0.16%	136

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Alta Wealth Advisors's TXG Position: Q4 2021 in Review

Alta Wealth Advisors sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 1,523 shares — an estimated $222K sold.

Alta Wealth Advisors first reported a position in TXG in Q3 2021 and held it in 1 quarter. The position peaked at $222K in Q3 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Alta Wealth Advisors reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
Alta Wealth Advisors sold 1,523 10x Genomics shares in Q4 2021, an estimated $222K.
Alta Wealth Advisors first reported a position in 10x Genomics in Q3 2021 and held it in 1 quarter.
Alta Wealth Advisors's 10x Genomics position peaked at $222K in Q3 2021.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Alta Wealth Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.